Welcome to our dedicated page for Indivior Pharmaceuticals SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Indivior PLC (NASDAQ: INDV) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a pharmaceutical issuer focused on opioid use disorder (OUD) treatments, Indivior uses its filings to report financial results, strategic initiatives, governance changes, and key legal and regulatory matters.
Investors can review Form 8-K current reports in which Indivior details material events such as quarterly financial results, updates on the Indivior Action Agenda, restructuring charges, optimization of its Rest of World business, and changes to executive compensation or board composition. Other 8-K items describe the company’s intent to redomicile from the U.K. to Delaware, shareholder approvals of a scheme of arrangement and amended articles of association, and the conclusion of a legacy U.S. Department of Justice resolution agreement.
Through its periodic reports (Forms 10-K and 10-Q, when available on EDGAR), readers can examine segment performance, revenue composition, R&D spending, and risk factors related to Indivior’s OUD-focused portfolio, including SUBLOCADE, SUBOXONE Film, PERSERIS, and OPVEE. These filings also typically include detailed discussions of non-GAAP measures such as adjusted EBITDA and non-GAAP operating expenses, along with reconciliations to U.S. GAAP metrics.
Stock Titan enhances these documents with AI-powered summaries that highlight the most important points in lengthy filings, helping users quickly understand changes in guidance, restructuring actions, legal exposures, or capital structure. Real-time updates from EDGAR mean that new Indivior filings, including any future proxy statements on executive compensation and Form 4 insider transaction reports, are surfaced promptly.
By using this page, investors, analysts, and other stakeholders can efficiently navigate Indivior’s SEC reporting history, monitor developments in its OUD pharmaceutical business, and interpret the financial and governance implications of its regulatory disclosures.
Indivior Pharmaceuticals, Inc. has entered into a $175 million accelerated share repurchase agreement (ASR) with Barclays Bank PLC as part of its previously authorized $400 million share repurchase program. Indivior made an upfront payment of $175 million and received an initial delivery of 3,717,473 common shares.
The final number of shares Indivior repurchases will depend on the volume weighted average price of its stock over the ASR term, less a discount, under the contract’s terms. Transactions under the ASR are expected to be completed by late June 2026, and Indivior does not expect this action to affect its previously issued financial guidance.
Indivior Pharmaceuticals, Inc. reported strong first-quarter 2026 results, led by its long-acting opioid use disorder treatment SUBLOCADE. Net revenue rose to $317 million from $266 million, while net income increased to $89 million from $47 million, lifting diluted EPS to $0.69.
SUBLOCADE net revenue grew 32% to $232 million, representing 73% of total net revenue, and gross margin improved to 87% as mix shifted toward higher-margin products. The company issued $500 million of 0.625% Convertible Senior Notes due 2031, repaid a $333 million term loan, and repurchased about 4 million shares for $125 million under a new $400 million buyback.
Operating cash flow turned slightly negative, mainly due to litigation settlement payments and payment timing, while restructuring tied to the Indivior Action Agenda continued, with $9 million of charges in the quarter and $40 million of related liabilities outstanding.
Indivior Pharmaceuticals, Inc. reported strong Q1 2026 results and raised its full-year 2026 outlook. Total net revenue rose to $317 million, up 19% year over year, driven by SUBLOCADE, which generated $232 million in net revenue, up 32%.
GAAP net income increased to $89 million from $47 million, with diluted EPS of $0.69. Non-GAAP net income was $123 million, and record quarterly Adjusted EBITDA reached $164 million, up 112%, for a 52% margin.
For 2026, the company now guides total net revenue to $1.215–$1.285 billion and SUBLOCADE net revenue to $950–$990 million, with Adjusted EBITDA of $620–$660 million and non-GAAP operating expenses of $430–$450 million. Indivior issued $500 million of convertible senior notes, repaid $333 million of term debt, and repurchased about $125 million of shares (~4 million), leaving $275 million on its authorization.
Indivior Pharmaceuticals Inc ownership reported by Vanguard Portfolio Management LLC: 7,994,836 shares, representing 6.55% of common stock as of 03/31/2026. The filing states Vanguard has sole dispositive power over 7,994,836 shares and sole voting power for 103,017 shares.
The filing notes these holdings include securities held for Vanguard funds and managed accounts and is signed by Ashley Grim on 04/28/2026.
Indivior Pharmaceuticals ownership disclosure: Vanguard Capital Management reports beneficial ownership of 6,523,720 shares, equal to 5.35% of Indivior common stock. The filing shows sole voting power over 937,144 shares and sole dispositive power over 6,523,720 shares.
Indivior Pharmaceuticals, Inc. is asking shareholders to vote at its 2026 virtual annual meeting on May 13, 2026, on four items: electing eight directors, approving executive pay on an advisory basis, choosing annual say‑on‑pay frequency, and ratifying PwC as auditor.
Management highlights 2025 as a strong transition year. Total net revenue rose 4% to $1.24 billion, driven by SUBLOCADE, whose net revenue grew 13% to a record $856 million. GAAP net income reached $210 million, and adjusted EBITDA increased 20% to $428 million with a 35% margin.
The company completed Phase I of its Indivior Action Agenda, simplified its operating model, and ended 2025 with net leverage of 0.7x. It resolved a legacy DOJ matter and authorized a $400 million share repurchase program, while re‑domiciling from the U.K. to Delaware and aligning governance and compensation with U.S. practices.
Indivior Pharmaceuticals Schedule 13G: Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of 4,806,556 shares of Common Stock, representing 3.8% of the class. The filing states that after acquiring beneficial ownership of more than 5% on March 17, 2026, the reporting persons ceased to be beneficial owners of more than 5% by the date of this filing.
The reported shares are held by entities subject to voting and investment discretion by Millennium Management LLC and related managers. A Joint Filing Agreement dated March 20, 2026 is attached and signatures are provided by the reporting persons.
Indivior Pharmaceuticals, Inc. Chief Financial Officer Ryan Preblick reported routine equity compensation activity. On March 14, 2026, 6,302 restricted stock units vested and converted into the same number of common shares. To cover tax withholding obligations, 2,843 of these shares were withheld at $31.11 per share, leaving a net increase of 3,459 shares. Following these transactions, Preblick directly holds 320,751 shares of Indivior common stock.
Indivior Pharmaceuticals, Inc. issued $500,000,000 of 0.625% Convertible Senior Notes due 2031. The Notes bear 0.625% interest, payable semi-annually, and mature on March 15, 2031, unless earlier repurchased, redeemed or converted.
Before December 16, 2030, holders may convert only upon certain events; afterward they may convert at any time until shortly before maturity. The company may settle conversions in cash and, if applicable, common stock. The initial conversion rate is 24.0033 shares per $1,000 principal amount, with customary anti-dilution adjustments and potential “make-whole” increases after specified corporate events.
The Notes are senior, unsecured obligations with standard events of default and conditional redemption and fundamental change repurchase features. A portion of the proceeds was used to prepay all outstanding principal, interest and fees under a prior Note Purchase Agreement, which was terminated on March 17, 2026. Initially, up to 16,202,200 shares of common stock may be issuable upon conversion based on an initial maximum conversion rate of 32.4044 shares per $1,000 principal amount.